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Statement of Translational Relevance 60 
 61 
 62 
Pancreatic cancers associated with a germline BRCA1/BRCA2 (gBRCA) mutation may 63 
be targetable using DNA-damaging agents, such as platinums and PARP inhibitors. 64 
However, treatment stratification based on germline mutational status alone, and 65 
assumed homologous recombination deficiency, is associated with heterogeneous 66 
outcomes. In this study, we combine a multi-institutional patient cohort and a multi-arm 67 
preclinical trial to identify biomarkers to guide treatment decisions. We propose a 68 
predictive and prognostic model of gBRCA-mutated pancreatic cancer based on 69 
genomic hallmarks of homologous recombination deficiency, Ki67 index, tumour ploidy 70 
and transcriptomic subtype. Since the basal-like transcriptomic subtype is associated 71 
with worse survival, we propose a novel and clinically pragmatic immunohistochemical 72 






Purpose: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline 76 
BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinums and poly(adenosine 77 
diphosphate-ribose) polymerase inhibitors (PARPi). However, treatment stratification 78 
based on gBRCA mutational status alone is associated with heterogeneous responses.  79 
 80 
Experimental Design: We performed a 7-arm preclinical trial consisting of 471 mice, 81 
representing 12 unique PDAC patient-derived xenografts, of which 9 were gBRCA-82 
mutated. From 179 patients whose PDAC was whole genome and transcriptome 83 
sequenced, we identified 21 cases with homologous recombination deficiency (HRD), 84 
and investigated prognostic biomarkers.  85 
 86 
Results: We found that biallelic inactivation of BRCA1/BRCA2 is associated with 87 
genomic hallmarks of HRD and required for cisplatin and talazoparib (PARPi) 88 
sensitivity. However, HRD genomic hallmarks persisted in xenografts despite the 89 
emergence of therapy resistance, indicating the presence of a genomic scar. We 90 
identified tumour polyploidy and a low Ki67 index as predictors of poor cisplatin and 91 
talazoparib response. In HRD PDAC patients, tumour polyploidy and a basal-like 92 
transcriptomic subtype were independent predictors of shorter survival. To facilitate 93 
clinical assignment of transcriptomic subtype, we developed a novel pragmatic two-94 





Conclusions: In summary, we propose a predictive and prognostic model of gBRCA-97 
mutated PDAC based on HRD genomic hallmarks, Ki67 index, tumour ploidy and 98 






Pancreatic ductal adenocarcinoma (PDAC) is a difficult-to-treat malignancy with a 9% 5-102 
year overall survival1,2. The inefficacy of unselected chemotherapy may reflect the 103 
molecular heterogeneity of PDAC. Recently, distinct genomic and transcriptomic 104 
subtypes of PDAC have been identified, and may inform treatment stratification3-6. 5-105 
10% of incident PDAC cases are associated with germline loss-of-function mutations in 106 
BRCA1, BRCA2, or PALB27,8. These genes are implicated in DNA damage response 107 
through homologous recombination repair (HRR)9.  108 
 109 
We have previously shown in vitro that BRCA1- and BRCA2-mutated PDAC cell lines 110 
are sensitive to platinums and poly(adenosine diphosphate-ribose) polymerase 111 
inhibitors (PARPi)10. Platinums induce DNA interstrand crosslinks, which lead to double-112 
strand breaks (DSB) that cannot be effectively repaired by homologous recombination 113 
deficient (HRD) cells11. PARP inhibitors prevent the repair of single-strand breaks (SSB) 114 
through several mechanisms, including PARP trapping. As SSBs progress to DSBs, the 115 
accumulation of DNA damage is synthetic lethal in replicating HRD cells12,13. 116 
 117 
Retrospective clinical series have suggested that patients with late-stage PDAC and a 118 
germline BRCA1 or BRCA2 (gBRCA) mutation may have a survival benefit with 119 
platinum-based treatment7,14-16. Recently, the POLO trial showed longer progression-120 




gBRCA-mutated metastatic PDAC17. However, 17% of gBRCA-mutated patients in this 122 
trial progressed on first-line platinum therapy, highlighting the heterogeneity in platinum 123 
responses. In gBRCA-mutated breast and ovarian cancer, the absence of biallelic 124 
BRCA1 or BRCA2 inactivation has been implicated in primary resistance to platinum 125 
therapy18. Reversion mutations that restore BRCA1 or BRCA2 function have been 126 
described as a mechanism of acquired resistance19,20. However, the majority of gBRCA 127 
tumours do not exhibit a reversion mutation at the time of disease relapse21. Together, 128 
these observations highlight the need to identify predictive biomarkers, beyond germline 129 
mutational status, in gBRCA-mutated PDAC. 130 
 131 
Here, we performed a multi-arm preclinical trial using mouse xenograft models derived 132 
from patients with gBRCA-mutated PDAC to evaluate their response to platinum and 133 
talazoparib, a second-generation PARPi with speculated higher potency. We 134 
demonstrate that HRD genomic hallmarks are required for sensitivity to platinum and 135 
PARPi therapy, whereas tumour polyploidy predicts poor response to these therapies. 136 
Furthermore, by integrating clinical and molecular profiling data from 21 patients with 137 
HRD PDAC, we suggest that tumour polyploidy and a basal-like transcriptomic subtype 138 
are poor prognostic variables in HRD PDAC.  139 
 140 
 141 






1. Biallelic, but not monallelic, BRCA1 or BRCA2 inactivation is associated with 145 
genomic hallmarks of HRD 146 
 147 
Since biallelic inactivation of BRCA1 or BRCA2 has been associated with treatment 148 
responses in other cancer types, we whole genome sequenced (WGS) 7 unique 149 
gBRCA-mutated PDAC cases selected for the preclinical trial (Supp. Table 1). Six of 150 
the 7 samples showed biallelic loss of BRCA1 (n = 2) or BRCA2 (n = 4), due to loss of 151 
heterozygosity of the wildtype allele or a second somatic mutation. In contrast, the 152 
remaining sample (Q437) exhibited only a germline BRCA2 mutation without a second 153 
somatic hit.  154 
 155 
Tumours with biallelic BRCA1 or BRCA2 inactivation had higher HRDetect scores 156 
compared to the sample with monoallelic loss (>0.999 vs. 0.042; Fig.1a). Biallelic 157 
inactivation cases exhibited a higher number of structural variants, driven by small 158 
deletions in the 100bp-10kbp range, consistent with rearrangement signature 5. They 159 
also displayed a single nucleotide variant (SNV) burden that was dominated by 160 
COSMIC single base substitution signature 3 (SBS3, 32.6% overall SNV), which is 161 
associated with defective homologous recombination repair22. In contrast, the case with 162 
monoallelic BRCA2 inactivation had 0% SBS3 proportion. These findings suggest that 163 




signatures, that are captured by a dominant SBS3 contribution and an elevated 165 
HRDetect score.  166 
 167 
2. HRD PDAC xenografts are preferentially sensitive to cisplatin and talazoparib mono- 168 
and combination therapy 169 
 170 
We evaluated 10 unique patient-derived xenografts (PDX) in a multi-arm preclinical trial 171 
(387 mice in total) to evaluate their response to platinum, PARPi and gemcitabine-172 
based therapy. Of these 10 PDXs, 6 had biallelic BRCA1 (n = 2) or BRCA2 (n = 4) 173 
inactivation, and genomic hallmarks of HRD as determined by WGS; these were 174 
considered HRD. The remaining xenografts had only monoallelic germline BRCA2 loss 175 
(n = 1) or did not harbour a germline HR gene mutation (n = 3), and were considered 176 
HR-proficient (HRP, Supp. Table 1, Supp. Fig. 1).  177 
 178 
After 28 days of treatment, HRD xenografts showed a significantly greater treatment 179 
response to cisplatin monotherapy (2.50 vs. 4.97 fold-change, p < 0.001), talazoparib 180 
monotherapy (2.35 vs. 5.73, p = 0.003) and cisplatin-talazoparib combination therapy 181 
(1.46 vs. 4.19, p < 0.001) compared to HRP xenografts (Fig. 1b-c). Gemcitabine 182 
monotherapy resulted in comparable tumour regression in both HRD and HRP 183 
xenografts (0.75 vs. 0.60, p = 0.46). Similarly, there was no difference in treatment 184 
response to combination gemcitabine-cisplatin or gemcitabine-talazoparib between 185 





Cisplatin-talazoparib combination resulted in greater tumour inhibition compared to 188 
talazoparib alone in both HRD (1.46 vs. 2.35, p = 0.040) and HRP xenografts (4.19 vs. 189 
5.73, p = 0.036). In HRD xenografts, there was a trend towards improved efficacy with 190 
cisplatin-talazoparib compared to cisplatin alone (1.46 vs. 2.50, p = 0.087); however, no 191 
difference was seen for HRP xenografts (4.19 vs. 4.97, p = 0.280). 192 
 193 
3. Gemcitabine-cisplatin is associated with prolonged survival in HRD PDAC 194 
xenografts  195 
 196 
Since HRD and HRP xenografts had similar tumour regression following 28 days of 197 
gemcitabine mono- or combination therapy, we assessed differences in treatment 198 
durability. We compared the median overall survival (mOS) of mice in each treatment 199 
arm (gemcitabine vs. gemcitabine-cisplatin vs. gemcitabine-talazoparib) for HRD and 200 
HRP xenografts. Since mice were monitored until their tumour reached endpoint size, 201 
we used mOS as a surrogate for treatment durability. In mice bearing HRD tumours, 202 
gemcitabine-cisplatin was associated with significantly longer mOS compared to 203 
gemcitabine alone (126 vs. 106.5 days, p = 0.048) and gemcitabine-talazoparib (126 vs. 204 
98 days, p < 0.001). There were no differences in mOS between gemcitabine and 205 
gemcitabine-talazoparib (106.5 vs. 98 days, p = 0.14). Median overall survival was 206 
similar between all 3 treatment arms in HRP xenografts (Fig. 1d-e). 207 
 208 
Gemcitabine-talazoparib was the most toxic regimen, with 31% of mice euthanized prior 209 




gemcitabine-cisplatin and gemcitabine monotherapy arms, respectively. To adjust for 211 
regimen-related toxicity, we repeated the survival analyses including only mice that 212 
completed 28 days of treatment. In HRD tumours, gemcitabine-cisplatin was again 213 
associated with longer mOS compared to gemcitabine alone (130 vs. 106.5 days, p = 214 
0.002) and gemcitabine-talazoparib (130 vs. 109 days, p = 0.020). Median OS was 215 
comparable between all 3 treatment arms for HRP tumours (Supp. Fig. 2). 216 
 217 
4. Gemcitabine-cisplatin and gemcitabine-talazoparib suppress tumour proliferation in 218 
HRD xenografts  219 
 220 
To investigate the antiproliferative effect of gemcitabine-based therapy, we evaluated 221 
the Ki67 index of PDXs at the end of treatment (day 29). HRD PDX treated with 222 
gemcitabine-cisplatin (0.34 vs. 0.57, p = 0.040) and gemcitabine-talazoparib (0.23 vs. 223 
0.60, p < 0.001) had a significantly lower relative Ki67 index compared to HRP tumours 224 
(Fig. 2a-b). With gemcitabine monotherapy, HRD PDX also had a lower relative Ki67 225 
index (0.38 vs. 0.63, p = 0.161), although this trend was not statistically significant. 226 
Additionally, the Ki67 index was significantly correlated with mitotic activity across all 227 
PDX (R = 0.692, p < 0.001) (Fig. 2c). Further, we evaluated cleaved caspase-3 (CC-3) 228 
immunostaining as a marker of apoptotic cell death. Gemcitabine-talazoparib was 229 
associated with significantly increased relative CC-3 positivity in HRD vs. HRP PDX 230 




residual tumour at the end of treatment, and were insufficient for Ki67 and CC-3 232 
immunostaining.  233 
   234 
 235 
5. Longitudinally-derived HRD xenografts recapitulate the emergence of clinical 236 
chemoresistance  237 
 238 
To study the evolution of treatment response to HRD-targeted therapies, we 239 
longitudinally derived 3 xenografts from a patient with biallelic BRCA2-mutated PDAC, 240 
over a 4.5-year disease course (Fig. 3a-b). The patient presented with a pancreatic tail 241 
PDAC and liver metastases. Following an exceptional response to FOLFIRINOX, a 242 
distal pancreatectomy (PDX #1, Q70P) and radiofrequency ablation of his liver 243 
metastases were performed. Two years later, a second xenograft was established 244 
(PDX#2, Q70LM) from new liver metastases. These liver metastases again responded 245 
to FOLFIRINOX. Finally, a third xenograft (PDX #3, Q70AM) was established from an 246 
abdominal wall metastasis at the time of disease progression. The patient died after 2 247 
additional cycles of platinum-based therapy (gemcitabine-cisplatin). 248 
 249 
To represent each patient by a single PDX, only the Q70P xenograft was included in the 250 
preclinical trial summarized in Figure 2. However, we also performed the 7-arm 251 
preclinical trial for the 2 longitudinal PDXs (Q70LM, Q70AM) to evaluate their treatment 252 




cisplatin (Q70P, 4.19 vs. 11.25 fold change, p < 0.001; Q70LM, 2.60 vs. 6.20, p < 254 
0.001), talazoparib (Q70P, 2.26 vs. 11.25, p < 0.001; Q70LM, 1.52 vs. 6.20, p < 0.001) 255 
and cisplatin-talazoparib (Q70P, 1.56 vs. 11.25, p < 0.001; Q70LM, 1.15 vs. 6.20, p < 256 
0.001) compared to vehicle, mirroring the clinically favourable response to FOLFIRINOX 257 
(Fig. 3c). In contrast, the Q70AM xenograft showed resistance to cisplatin (4.00 vs. 258 
4.92, p = 0.22) and talazoparib (4.40 vs. 4.92, p = 0.69) monotherapy. However, this 259 
xenograft remained sensitive to cisplatin-talazoparib combination (2.29 vs. 4.92, p < 260 
0.001). 261 
 262 
To understand the mechanisms underlying this acquired resistance, we whole genome 263 
sequenced the patient’s abdominal wall metastasis (Q70AM). The germline and somatic 264 
inactivating BRCA2 mutations found in the Q70P tumour were conserved in the Q70AM 265 
tumour. Both tumours had elevated HRDetect scores (>0.99) and had SNV mutational 266 
patterns dominated by SBS3 (Fig. 4a). However, while the Q70P tumour was diploid, 267 
the Q70AM tumour was polyploid. The liver metastasis (Q70LM) sample had insufficient 268 
cellularity for WGS, but we determined that it had also become polyploid using SNP 269 
array profiling and flow cytometric cell cycle analysis (Supp. Fig. 4).  270 
 271 
6. A genomic scar persists in HRD xenografts treated with gemcitabine-cisplatin 272 
 273 
To characterize changes in the genomic landscape of HRD xenografts following 28 274 




included (1) patient primary, (2) untreated parent PDX and (3) PDX treated with 276 
gemcitabine-cisplatin (GC) for 28 days, and collected at humane endpoint. We profiled 277 
xenografts from the GC arm, since this regimen showed the strongest and most 278 
sustained treatment response. We hypothesized that tumours that regrew following 279 
treatment cessation would have an increase in non-HRD-associated mutational 280 
signatures related to expansion of resistant subclonal populations under selective 281 
therapy pressure. Additionally, to evaluate the impact of prior chemotherapy exposure, 282 
we characterized PDXs from patients that were both chemo-naïve (Q392, O232) and 283 
chemo-treated (Q70P, Q70AM).  284 
 285 
Germline and somatic BRCA2 mutations were conserved in both the untreated parent 286 
and GC-treated xenografts across all trios, and there was no evidence of a reversion 287 
mutation in trial endpoint PDXs (Fig. 4a). Similarly, HRDetect scores remained high 288 
(>0.99) in both untreated parent and GC-treated xenografts. There was no significant 289 
decrease in SBS3 proportion in the GC-treated xenografts, compared to the untreated 290 
parent xenografts (26.3 vs. 29.3%, p = 0.89).  291 
 292 
Next, we evaluated the SNVs private to the GC-treated xenografts, and which 293 
presumably accumulated on treatment. Interestingly, these private SNVs continued to 294 
show SBS3 mutational patterns (Supp. Fig. 5). In 3 of 4 cases, we also observed SBS3 295 
variants private to the untreated parent xenograft, suggesting that a fraction of HRD 296 




Q70AM tumour, which was chemoresistant both clinically and in the preclinical trial, 298 
retained an elevated SBS3 proportion and HRDetect score. These data suggest that a 299 
genomic HRD scar persists despite the emergence of resistance. 300 
 301 
GC-treated xenografts had a higher neoantigen load compared to their matched 302 
untreated xenograft (161 vs. 134, p = 0.02, Fig. 4b). Importantly, the Q70AM patient 303 
tumour, which received several additional cycles of platinum-based chemotherapy 304 
compared to the Q70P primary, exhibited a higher neoantigen load (122 vs. 82). This 305 
observation was corroborated by a higher degree of CD8+ cytotoxic T-cell infiltration in 306 
the Q70AM tumour compared to the Q70P primary, albeit not to levels typically seen in 307 
mismatch repair-deficient PDAC (Fig. 4c).  308 
 309 
7. Tumour polyploidy and low Ki67 associated with poor response to platinum and 310 
PARPi 311 
 312 
Among xenografts exhibiting genomic HRD hallmarks, we observed heterogeneity in 313 
individual tumour responses to cisplatin and talazoparib therapy. We searched for 314 
additional biomarkers that may be predictive of treatment response. All HRD and HRP 315 
xenografts were whole transcriptome sequenced, and their Moffitt transcriptomic 316 
subtype was determined relative to 167 PDAC transcriptomes, 164 of which were 317 
sequenced in the COMPASS trial23 (NCT02750657). Of the 8 HRD xenografts, 4 were 318 




(Fig. 5a). Additionally, all HRP xenografts were profiled using a SNP array to determine 320 
their ploidy (Supp. Fig. 4). 321 
 322 
We performed stepwise multivariate linear regression to identify independent predictors 323 
of cisplatin (Fig. 5b) and talazoparib (Fig. 5c) response. In the cisplatin model, genomic 324 
hallmarks of HRD (β = –0.478, p < 0.001) and a higher Ki67 (β = –0.257, p = 0.005) 325 
were independently associated with better response, whereas tumour polyploidy (β = 326 
0.600, p < 0.001) was associated with poor response. In the talazoparib model, HRD 327 
genomic hallmarks (β = –0.299, p = 0.002) and a basal-like transcriptomic subtype (β = 328 
–0.442, p < 0.001) were predictive of treatment response. A higher Ki67 index (β = –329 
0.192, p = 0.059) was also associated with better talazoparib response, although this 330 
trend missed statistical significance. Tumour polyploidy (β = 0.449, p < 0.001) was 331 
again associated with poor response in the talazoparib model. 332 
 333 
To illustrate the heterogeneity in treatment responses across individual xenografts, we 334 
performed principal component analysis (PCA) followed by k-means clustering to group 335 
xenografts based on their sensitivity to cisplatin, talazoparib and cisplatin-talazoparib 336 
(Supp. Fig. 6). Cluster 1 identified the best responders, of which all were HRD and 337 
diploid, except Q70LM which was a polyploid HRD case with high Ki67. Cluster 2 338 
represented the intermediate responders, which included an HRP case (Q155), a case 339 
with monoallelic BRCA2 inactivation and low HRDetect score (Q437) and a polyploid 340 




treatment response, of which 2 were HRP, while the third was a polyploid, low-Ki67, 342 
HRD case that had developed chemoresistance (Q70AM). 343 
 344 
Across the xenografts evaluated in the preclinical trial, we observed sustained complete 345 
responses in 2 cases: O217 and O28. Interestingly, both were diploid, high Ki67, HRD 346 
cases from Cluster 1. Both xenografts showed sustained complete responses with 347 
gemcitabine-cisplatin (median follow-up 237 days) and cisplatin-talazoparib (median 348 
follow-up 248 days). The O217 case also showed a sustained complete response with 349 
gemcitabine-talazoparib (median follow-up 252 days).  350 
 351 
 352 
8. Tumour polyploidy and a basal-like transcriptomic subtype are associated with 353 
worse prognosis in HRD PDAC 354 
 355 
To evaluate the prognostic relevance of these biomarkers, we identified 21 patients with 356 
PDAC exhibiting genomic HRD hallmarks based on WGS. In addition to the 6 patients 357 
whose tumours were evaluated in the preclinical trial, we also included 12 HRD PDAC 358 
patients enrolled in the COMPASS trial and 3 additional HRD PDAC patients with whole 359 
genome and whole transcriptome sequencing data (Supp. Table 2). 360 
 361 
The median OS for all patients was 25.9 months (95% CI 0-51.9 months). Patients with 362 




53.9 months, p = 0.008) (Fig. 6a). Additionally, patients with a basal-like PDAC had 364 
shorter mOS compared to those of classical transcriptomic subtype (25.9 vs. 38.5 365 
months, p = 0.081) (Fig. 6b). We performed a multivariable Cox regression analysis 366 
with stepwise forward selection, including age, sex, stage, tumour ploidy and Moffitt 367 
transcriptomic subtype. Tumour polyploidy (HR 8.6, p = 0.007) and a basal-like 368 
transcriptomic subtype (HR 5.0, p = 0.033) were independently associated with mortality 369 
(Fig. 6c). After adjusting for stage and sex, a basal-like subtype remained 370 
independently predictive of poor survival, whereas tumour polyploidy trended towards 371 
significance (Supp. Fig. 7).  372 
 373 
This clinical series included 3 patients who have been disease-free for over 5 years, of 374 
which 2 initially presented with locally advanced disease. Interestingly, all 3 long-term 375 
survivors had classical, diploid HRD PDAC.  376 
 377 
 378 
9. GATA6:KRT17 ratio is an immunohistochemical discriminator of classical versus 379 
basal-like transcriptomic subtype 380 
 381 
Since basal-like HRD PDAC was associated with worse prognosis, we searched for 382 
clinically practical biomarkers that could robustly predict transcriptomic subtype. Using 383 
the combined COMPASS and PDX cohorts, we compared the normalized gene 384 




basal-like PDAC. GATA6 expression was significantly higher in classical tumours (p = 386 
2.53e-17) whereas KRT17 and KRT81 expression were significantly higher in basal-like 387 
tumours (KRT17, p = 1.59e-4; KRT81, p = 5.12e-4, Fig. 7a). To validate these findings, 388 
we performed IHC staining on tissue microarrays of HRD PDAC xenografts with known 389 
Moffitt subtype. High GATA6 staining was predictive of the classical subtype with an 390 
area under the curve (AUC) of 0.902, whereas high KRT17 staining was predictive of 391 
the basal-like subtype with an AUC of 0.828. The combination of these 2 markers as a 392 
GATA6:KRT17 ratio had higher predictive value than either marker alone, with an AUC 393 
of 0.971 (Fig. 7b-d). Using a clinically pragmatic cutoff of 1, the GATA6:KRT17 ratio 394 
has a sensitivity of 100% and a specificity of 83.3%.  395 
 396 
We also performed multiplex IHC (mIHC) to investigate the colocalization of these 397 
seemingly complementary markers. Tumours stained predominantly for one of the two 398 
markers, and only 14.9% of cells were dual-positive for GATA6 and KRT17. 399 
Interestingly, we observed discrete subpopulations of GATA6+/KRT17- and GATA6-400 
/KRT17+ cells within the same xenograft (Fig. 7e). This intratumoral heterogeneity was 401 
also found in the corresponding patient tumour (Supp. Fig. 8). Finally, we found KRT81 402 
IHC to be a poor predictor of transcriptomic subtype, with an AUC of 0.519. 403 
 404 





We established primary cell cultures from 8 gBRCA-mutated patient-derived xenografts 407 
(Supp. Table 3). Of these, 3 cell lines were spontaneously immortal, and could be 408 
propagated beyond 40 passages without exogenous growth factor stimulation. 409 
Interestingly, these immortal cell lines were all derived from polyploid tumours (Q70LM, 410 
Q70AM, S145). In contrast, the 5 remaining primary cell cultures that were generated 411 
from diploid PDAC xenografts could only be maintained in vitro for a finite period, 412 






The advent of next-generation sequencing (NGS) has accelerated the identification of 416 
molecular subtypes of PDAC with targeted therapy opportunities. However, comparing 417 
molecular-guided treatments head-to-head using conventional clinical trial designs is 418 
impractical24,25. To overcome these challenges, we combined a multi-institutional patient 419 
cohort and rare PDX models to identify biomarkers underlying the therapeutic and 420 
prognostic heterogeneity of gBRCA-mutated PDAC, which is the most prevalent 421 
druggable PDAC subtype. 422 
 423 
We found that biallelic, but not monoallelic, inactivation of BRCA1/BRCA2 was 424 
associated with mutational signatures characteristic of HR deficiency, including SBS3 425 
and HRDetect. We showed that xenografts exhibiting HRD genomic hallmarks were 426 
preferentially sensitive to cisplatin, talazoparib, and the combination of these therapies. 427 
This has important treatment and economic implications, considering that routine 428 
germline testing is becoming standard of care in PDAC26, and there is indication to treat 429 
gBRCA-mutated platinum-sensitive PDAC with PARPi based on the POLO trial17. 430 
However, cases of monoallelic BRCA1/BRCA2 inactivation may not respond to platinum 431 
and PARPi therapies. Therefore, integration of companion FFPE tissue-based NGS 432 
assays (Myriad myChoice HRD, FoundationFocus CDxBRCALOH) will be important to 433 





Treatment responses to gemcitabine-cisplatin and gemcitabine-talazoparib were 436 
comparable between HRD vs. HRP xenografts, and were driven by the high efficacy of 437 
gemcitabine. Considering the clinical response rates to gemcitabine, these preclinical 438 
observations may reflect differences in intratumoral drug delivery and tumour immune 439 
microenvironment in subcutaneous xenograft models. Nonetheless, the combination of 440 
gemcitabine-cisplatin yielded the most durable treatment response in our preclinical 441 
trial, in addition to a significant antiproliferative effect compared to gemcitabine alone.  442 
 443 
Akin to clinical observations17, we found heterogeneity in treatment responses among 444 
the HRD PDAC xenografts. We identified tumour polyploidy as an independent predictor 445 
of poor platinum and PARPi response. This finding is consistent with previous reports 446 
showing that polyploid cells are resistant to cytotoxic drugs29,30. We also found that 447 
xenografts with a higher Ki67 index had a better response to cisplatin. We identified a 448 
similar trend with talazoparib, although this did not achieve statistical significance, 449 
possibly reflecting our sample size. These observations are in concordance with studies 450 
in triple-negative breast cancer and enteropancreatic neuroendocrine tumours, in which 451 
a high Ki67 index predicts better initial responses to chemotherapy, but do not translate 452 
to improved survival. To this end, Ki67 index did not correlate with survival in our study, 453 
and its prognostic value in HRD PDAC remains unclear.  454 
 455 
Additionally, in our cohort of HRD PDAC patients, tumour polyploidy was independently 456 




routine testing of clinical specimens using SNP genotyping assays that capture 458 
genome-wide copy number aberrations. 459 
 460 
Interestingly, we found that cell lines derived from polyploid gBRCA-mutated tumours 461 
were spontaneously immortal, whereas those generated from diploid tumours became 462 
senescent. These observations support polyploidy as an aggressive tumour 463 
characteristic, and are consistent with our finding of polyploidy as a marker of poor 464 
treatment response and prognosis in gBRCA-mutated PDAC. Capan-1, the only 465 
published BRCA2-mutated pancreatic cancer cell line, has a hypotriploid genome31. We 466 
provide three additional polyploid gBRCA-mutated cell lines for in vitro studies. 467 
Importantly, the S145 cell line represents the first human BRCA1-mutated PDAC cell 468 
line. 469 
 470 
Although the Q70AM xenograft was resistant to cisplatin and talazoparib 471 
monotherapies, combination of these therapies yielded a treatment response. We also 472 
observed an additive treatment benefit when combining cisplatin with talazoparib in the 473 
preclinical trial. These findings suggest a synergistic effect of combining platinums and 474 
PARPi in HRD PDAC. Importantly, talazoparib is a second-generation PARPi with 475 
higher PARP1 trapping potency and relatively high catalytic inhibition compared to 476 
earlier generation PARPis (e.g., olaparib and veliparib), which have been previously 477 




talazoparib in multiple patient-derived tumours, providing motivation to evaluate 479 
talazoparib alone or in combination with platinums in a clinical trial setting. 480 
 481 
This study is the first to investigate the implications of Moffitt transcriptomic subtypes in 482 
HRD PDAC. We identified a similar proportion of classical versus basal-like PDAC in 483 
our series compared to published cohorts3,23. The basal-like subtype has been 484 
associated with shorter survival, and poor response to 5-FU/leucovorin (adjuvant)32 and 485 
FOLFIRINOX (metastatic first-line)23 in PDAC. In our HRD PDAC series, we found that 486 
a basal-like transcriptomic subtype was independently predictive of worse prognosis. 487 
Since there is growing evidence that discriminating between basal-like and classical 488 
transciptomic subtypes has clinical implications not only for HRD PDAC but across 489 
PDAC, we developed a novel, clinically pragmatic two-marker immunohistochemical 490 
assay (GATA6:KRT17). We showed its ability to discriminate between the classical and 491 
basal-like subtypes with 100% and 83.3% sensitivity and specificity, respectively.  492 
 493 
For advanced-stage gBRCA-mutated PDAC, retrospective series have shown a survival 494 
benefit with platinum-based therapy7,14,16. In this preclinical trial, the Moffitt subtype was 495 
not predictive of response to cisplatin after adjusting for HRD genomic hallmarks. This 496 
findings suggests a hierarchy where HRD genomic features dictate platinum sensitivity 497 





We found that xenografts treated with gemcitabine-cisplatin retained genomic hallmarks 500 
of HRD and an elevated HRDetect score. Similarly, we demonstrated in a longitudinal 501 
study that a patient tumour that had acquired clinical chemoresistance retained a high 502 
HRDetect score. These findings suggest that HRD tumours develop a genomic scar that 503 
is the result of HRD-driven genomic mutations, and that these genomic hallmarks may 504 
not be an accurate indicator of ongoing sensitivity to HRD-targeting therapies. Thus, 505 
integrating functional assays, such as the RAD51 assay, alongside mutational 506 
signature-based biomarkers, may be a more precise strategy to select patients likely to 507 
benefit from HRD-targeted therapy33,34.  508 
 509 
Comparison of untreated vs. GC-treated PDXs revealed SBS3 variants private to the 510 
untreated xenografts, suggesting that a fraction of HRD clones may have been 511 
eliminated with treatment. This observation provides support that therapies targeting HR 512 
deficiency can eradicate, rather than only suppress, HRD PDAC cells.  513 
 514 
We have previously shown that HRD PDAC typically exhibits a higher mutational 515 
burden than “sporadic” PDAC, albeit lower than mismatch-repair deficient PDAC35. The 516 
inherent susceptibility of HRD PDAC to platinum-induced DNA damage may accelerate 517 
the production of tumour-specific neoantigens, and promote an antitumour immune 518 
response. In this study, we found an increase in neoantigen load in HRD PDAC 519 
xenografts following treatment with gemcitabine-cisplatin. This observation was 520 




parallel increase in peritumoral cytotoxic T-cell infiltration that coincided with exposure 522 
to platinum-based treatment exposure. Thus, HRD PDAC may be well-suited to 523 
treatment approaches that strategically combine or sequence platinum-based therapies, 524 
or even PARPi, with immunotherapy36,37. 525 
 526 
In summary, we combined a multi-institutional patient cohort and rare preclinical models 527 
to develop a treatment sensitivity and prognostic model (Fig. 8) of gBRCA-mutated 528 
PDAC. Further, we introduce a novel, clinically pragmatic 2-marker assay that is 529 
predictive of transcriptomic subtype and suggest a potential role for platinum-PARPi 530 
combinations as well as immunotherapy approaches in HRD PDAC. 531 
 532 
 533 








Patients with germline BRCA1 or BRCA2-mutated PDAC were identified from 3 539 
institutions: McGill University Health Centre, Montreal, Canada; Princess Margaret 540 
Cancer Centre, Canada; Chaim Sheba Medical Centre, Israel. Patients enrolled in the 541 
COMPASS molecular profiling trial (NCT02750657) from December 2015 to April 2019 542 
were also included. Patient demographics, surgical procedure, chemotherapy treatment, 543 
and survival data were abstracted from prospectively maintained institutional research 544 
databases. Clinical staging was based on the 8th edition of the American Joint 545 
Committee on Cancer (AJCC) for pancreatic ductal adenocarcinoma. Survival was 546 
calculated from the initial date of pathologic diagnosis until death or censor date.  547 
 548 
 549 
Germline sequencing of homologous recombination proficient cases 550 
 551 
Homologous recombination proficient (HRP) cases included in the preclinical trial were 552 
identified by sequencing for germline mutations in HRD genes using a targeted panel of 553 
710 cancer-related genes, including full gene sequencing of BRCA1, BRCA2, PALB2 554 
and ATM. The targeted regions were captured using Agilent SureSelect technology 555 








Whole genome sequencing (WGS) 561 
 562 
Fresh frozen human and xenograft tumour tissue underwent laser capture 563 
microdissection for tumour cell enrichment prior to DNA extraction. WGS of tumour and 564 
matched lymphocyte DNA was performed at the Ontario Institute for Cancer Research 565 
using established institutional pipelines38. Germline and somatic variant calling, ploidy 566 
determination, neoantigen quantification protocols have been previously described. 567 
HRDetect scores were calculated as described by Davies et al39. Mutational signature 568 
proportions were derived by applying a non-negative least squares linear algorithm, as 569 
previously reported40. All germline mutations and somatic hits were confirmed in 570 
xenografts by Sanger sequencing.  571 
 572 
 573 
RNA sequencing  574 
 575 
Xenograft tumour tissues were preserved in RNAlater, and disrupted and homogenized 576 
using the Qiagen TissueLyser II (Qiagen, Manchester, UK). RNA was extracted using 577 




performed by BGI Americas and the McGill University Genome Quebec Innovation 579 
Centre (MUGQIC). Libraries were sequenced on the Illumina HiSeq 2000 (BGI) or 580 
HiSeq 2500 (MUGQIC) platforms with TruSeq V3 reagents, to generate 100bp paired-581 
end reads at a sequencing depth of 50 million reads.  582 
 583 
Adaptor sequences and low-quality score bases (Phred score < 30) were trimmed using 584 
Trimmomatic41. The resulting reads were aligned to the human genome reference 585 
sequence (GRCh38/hg38), using STAR42. To remove possible contaminated reads 586 
originating from mouse in xenograft samples, reads were also aligned to the 587 
GRCm38/mm10 mouse, and the Disambiguate algorithm (version 1.0)43 was used to 588 
assign reads to individual species based on the highest quality alignment of the read 589 
pair (Supp. Fig. 9). Count data (originating from human reads) for each sample were 590 
obtained using HTSeq44. For downstream analyses, we excluded lowly-expressed 591 
genes with an average read count lower than 10 across all of the samples. Raw counts 592 
were normalized using the TMM algorithm (i.e., weighted trimmed mean of M-values), 593 
implemented in edgeR R package45 (version 3.22.5). Using the voom function in the 594 
limma R package46 (version 3.36.5), the data were converted to log-counts per million. 595 
The removeBatchEffect function from limma was used to correct for both batch effects. 596 
Heatmaps were constructed using unsupervised hierarchical clustering (ward.D2 597 
method). Transcriptomic classification into classical and basal-like subtypes was 598 






Establishment of patient-derived xenografts 602 
 603 
Mice were housed in a pathogen-free facility, on a 12-hour light-dark cycle, with ad lib 604 
access to water and sterile rodent chow. Fresh PDAC tissue was obtained from the 605 
operating theater or interventional radiology suite, minced into 1mm3 pieces, and 606 
subcutaneously implanted into the flanks of 6-8-week-old female SCID beige mice 607 
(Charles River, Wilmington, MA, USA). Xenografts were grown to 1cm3, harvested and 608 
serially passaged into new SCID beige mice. Tumours were cryopreserved in fetal 609 
bovine serum (FBS) with 10% dimethyl sulfoxide. 610 
 611 
 612 
Multi-arm preclinical trial design 613 
 614 
Fourth-passage patient-derived tumours were implanted into the right and left flanks of 615 
6-8 week old female SCID beige mice. When the tumour volume reached 120mm3, mice 616 
were randomized to one of seven treatment arms with the goal of treating 6-10 mice per 617 
arm. The treatment arms were: (1) Cisplatin (Enzo Life Sciences, Brockville, ON, 618 
Canada) 4mg/kg, once weekly, intraperitoneal; (2) Talazoparib (Abmole Biosciences, 619 
Hong Kong) 0.33mg/kg, 5 days on/2 days off, oral gavage; (3) Cisplatin-Talazoparib 620 
combination; (4) Gemcitabine (LC Laboratories, Woburn, MA, USA) 100mg/kg, twice 621 




Talazoparib combination; (7) Vehicle (PBS) 5 days on/2 days off oral gavage, and once 623 
weekly intraperitoneal. Since pilot experiments showed increased toxicity with 624 
talazoparib (data not shown), we randomized at least 10 mice into the talazoparib arms, 625 
in anticipation that a greater fraction of mice in these arms may not complete the 626 
treatment course. Treatment was administered for 28 days, with half-dosing or skipped 627 
dosing, if mice lost >10% or >12.5% of their original weight, respectively. Mice were 628 
weighed, and tumours were measured by caliper twice weekly. Mice were euthanized 629 
when the tumour volume exceeded 2cm3, or if they lost >20% of their original weight. 630 
 631 
  632 
Tissue Microarrays 633 
 634 
Tissue microarrays were constructed using an automated tissue microarrayer (TMA 635 
Grand Master, 3DHistech, Budapest, Hungary). Freshly harvested PDX tumours were 636 
fixed in 10% buffered formalin for 24 hours, and paraffin-embedded. Tumour cores 637 
(2mm diameter) were punched from each donor paraffin-embedded block based on 638 
previously demarcated areas on a corresponding H&E stained slide. Each individual 639 
patient was represented by 2-3 unique PDX cores originating from early-passage mice. 640 
Overall, 33 cores representing 12 unique HRD PDAC xenografts were prepared on a 641 
TMA, which was sectioned at 4um thickness for subsequent immunohistochemical 642 






Single-marker and multiplex immunostaining  646 
 647 
4um serial sections of tissue microarray and patient tumour blocks were cut for 648 
hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) analyses. IHC 649 
was performed using the Discovery Ultra autostaining platform (Ventana Medical 650 
Systems, Tucson, AZ, USA). Slides were incubated with a primary antibody, followed by 651 
the corresponding horseradish peroxidase (HRP)-conjugated secondary antibody 652 
(OmniMap anti-mouse #760-4310 or OmniMap anti-rabbit #760-4311, Ventana), 653 
developed with 3,3’-diaminobenzidine (DAB) and counterstained with hematoxylin. 654 
Primary antibodies used were as follows: anti-Ki67 (30-9, Ventana, undiluted), anti-655 
cleaved caspase-3 (Asp175, Cell Signaling Technology, 1:100), anti-CD8 (SP57, 656 
Ventana, undiluted), anti-pancytokeratin (AE1/AE3/PCK26, Ventana, undiluted), anti-657 
GATA6 (D61E4, Cell Signaling Technology, 1:500), anti-KRT17 (17516-1-AP, 658 
Proteintech, 1:100), anti-KRT81 (11342-1-AP, Proteintech, 1:50). Multiplex chromogenic 659 
IHC was also performed on the Discovery Ultra platform, using chromogenic detection 660 
kits from Ventana (#750-124, DAB; #760-247, teal).  661 
 662 
 663 





Immunostained slides were scanned using the Aperio Scanscope (Aperio Technologies, 666 
Vista, CA, USA) at 20x magnification. For Ki67 immunostaining, five regions of interest 667 
were randomly selected for each tumour, and manually annotated to exclude stromal 668 
and necrotic areas by a technician blinded to treatment assignment. Ki67 669 
immunostaining was quantified by digital analysis of positively staining nuclei using the 670 
Aperio ImageScope software (Aperio Technologies, Vista, CA, USA). Cleaved caspase-671 
3, GATA6, KRT17 and KRT81 immunostaining were quantified using the Halo (Indica 672 
Labs, Corales, NM, USA) cytonuclear algorithm (single-marker) or multiplex IHC 673 
algorithm (multiplex IHC). A tissue classifier was developed to automatically segment 674 
tumour from stroma and necrosis. Cell recognition and nuclear segmentation were 675 
optimized, and quality control was performed for each case.  676 
 677 
Hematoxylin-eosin stained sections were reviewed by a board-certified gastrointestinal 678 
pathologist (S.F.). Mitotic figures were counted manually, and expressed as the number 679 
of mitotic figures per 10 high-power fields.  680 
 681 
 682 
Generation of primary cell cultures from HRD xenografts  683 
 684 
Harvested xenograft tumours were mechanically minced, and underwent serial trypsin 685 
digestion at 37°C. Murine fibroblast contamination was eliminated by magnetic-activated 686 




USA). Cells were seeded on collagen-coated plates and cultured in RPMI 688 
supplemented with 10% FBS and 1% antibiotic/antimycotic solution, at 37°C in a 689 
humidified incubator with a 5% CO2 atmosphere. Cell numbers were counted by trypan 690 
blue exclusion assay with a hematocytometer at 24-hour intervals for 7 days. Cell 691 
doubling times were calculated using a nonlinear regression (exponential growth 692 
equation) analysis. 693 
 694 
Tumour ploidy determination 695 
  696 
Q70P, Q70LM and Q70AM primary cell lines were generated as described above. Cells 697 
were harvested by centrifugation, fixed with ethanol, and incubated in 0.5mL cell cycle 698 
buffer containing 30ug/mL propidium iodide (PI, Sigma-Aldrich, USA) and 50ug/mL 699 
RNase A (Thermo Scientific, USA). PI fluorescence data were collected from 10,000 700 
cells on a flow cytometer, after gating to exclude dead cells, debris and doublets48. The 701 
Q70P cell line was used as a control to fix the voltage for the diploid population. DNA 702 
histograms were plotted using FlowJo (Tree Star Inc., Ashland, OR, USA). 703 
 704 
To determine the ploidy of the HRP cases, genomic DNA was extracted from early-705 
passage xenografts and single nucleotide polymorphism (SNP) array was performed 706 
using the Illumina Infinium Omni2.5 microarray. The allele-specific copy number 707 
analysis of tumors (ASCAT, v2.4.3) algorithm was used to infer tumour ploidy and 708 




“tumour-only” mode, using the 'Illumina2.5M' profile within ASCAT. The ploidy estimates 710 




Statistical analyses were performed using R software version 3.5 (R Foundation for 715 
Statistical Computing, Vienna, Austria) and Graphpad Prism, version 6 (Graphpad, CA, 716 
USA). Differences between continuous variables were compared using the Wilcoxon 717 
rank sum test. For forward stepwise multiple linear regression analysis, the criteria for 718 
entry into the model was p < 0.1 and for removal was p > 0.15. Overall survival was 719 
estimated using the Kaplan-Meier method and compared between treatment groups 720 
using a log-rank test. Hazard ratios were calculated using the Cox proportional hazards 721 
model. A p-value < 0.05 was considered statistically significant.  722 
 723 
Study Approval 724 
Use of human biospecimens and data was approved by the local institutional review 725 
boards of each participating centre. Patients provided written informed consent to 726 
participate. Animal studies were approved by the McGill University Animal Care 727 
Committee, and conducted in accordance with Animal Research: Reporting of In Vivo 728 


















































































Figure 1. Genomic characteristics of patient-derived xenografts and preclinical trial outcomes. (a) Genomic 
characteristics of the 7 gBRCA-mutated PDAC cases evaluated in the preclinical trial. The first 6 cases have 
biallelic inactivation of BRCA1 or BRCA2. They exhibit mutational patterns that are characteristic of homologous 
repair deficiency, and have an elevated HRDetect score. In contrast, the Q437 case with monoallelic BRCA2 
inactivation lacks these genomic HRD hallmarks and has a low HRDetect score. (b-c) 7-arm preclinical trial to 
evaluate response of PDAC xenografts to cisplatin, talazoparib and gemcitabine mono- and combination therapies. 
(b) HR-deficient (6 unique cases, 228 mice) and (c) HR-proficient (B, 4 unique cases, 159 mice) PDAC xenografts 
were treated for 28 days. For each treatment arm, the relative tumour growth (at Day 28) of HR-deficient vs. HR-
proficient xenografts was compared using multiple linear regression models. Tal, talazoparib; ** p < 0.01; *** p < 
0.001. (d-e) Kaplan-Meier survival curves of xenografts treated with gemcitabine mono- and combination therapies. 
In HR-deficient xenografts, gemcitabine-cisplatin was associated with longer survival than gemcitabine alone and 
gemcitabine-talazoparib. There was no survival difference in HR-proficient xenografts. P-values represent log-rank 








Figure 2. Histopathological and immunohistochemical analyses of proliferative 
activity in xenografts treated with gemcitabine mono- and combination therapies. 
(a) Comparison of relative Ki67 positivity of HR-deficient vs. HR-proficient xenografts for 
each treatment arm. * p < 0.05, *** p < 0.001. (b) Representative Ki67 immunostaining 
of Q392 (HR-deficient) vs. Q133 (HR-proficient) xenografts. GC, gemcitabine-cisplatin; 
GT, gemcitabine-talazoparib. (c) Pearson’s correlation between absolute Ki67 positivity 







































Figure 3. Longitudinally derived xenografts from a patient with HRD PDAC (Q70) 
recapitulate the emergence of clinical chemoresistance. (a) Timeline showing the 
evolution of serum Ca19-9 in relation to chemotherapy. Arrows indicate when the 
individual xenografts (Q70P, Q70LM, Q70AM) were derived. Numbers correspond to 
cross-sectional imaging detailed in (B). (b) Representative computed tomography scans 
showing chemotherapy response at various time points. (1-2) Partial response of the 
pancreatic tail primary (Q70P) to FOLFIRINOX. (3-4) Partial response of the liver 
metastases (Q70LM) to FOLFIRINOX. (5-6) Worsening of peritoneal carcinomatosis 
(Q70AM) on gemcitabine-cisplatin. (c) Multi-arm preclinical trial results for the Q70P, 
Q70LM and Q70AM xenografts (n = 117 mice). For a given xenograft, day 29 tumour 
ratios were compared between each treatment arm (cisplatin, talazoparib, cisplatin-
talazoparib) and vehicle. The Q70AM xenograft showed resistance to cisplatin and 
talazoparib alone, but remained sensitivity to cisplatin-talazoparib combination.  


































































Figure 4. Whole genome sequencing (WGS) of 4 matched HRD PDAC trios to 
evaluate genomic changes on chemotherapy. (a) For each case, WGS of the (1) 
patient primary, (2) untreated parent PDX (Pre), and (3) PDX treated with gemcitabine-
cisplatin and collected at trial endpoint (Post) are shown. Germline and somatic BRCA2 
mutations were conserved in all cases. The proportion of SBS3 remained stable in the 
gemcitabine-cisplatin-treated xenografts. (b) Evolution of neoantigen load between the 
patient, untreated parent PDX and PDX treated with gemcitabine-cisplatin. (c) Multiplex 
IHC stains showing spatial distribution of CD8+ (brown) cytotoxic T cells and pan-
cytokeratin+ (teal) PDAC cells. Consistent with the increase in in silico-predicted 
neoantigens, there is an increase in CD8+ infiltration in the Q70AM tumour compared to 






















Excluded: Ki67, chemotherapy status!
Variable Standardized coefficient (β) p-value
HRD -0.299 0.002


















Figure 5. Predictive biomarkers identified based on preclinical trial treatment 
responses. (a) Consensus clustered heatmap of PDAC transcriptomes split by Moffitt 
classical and basal-like factor gene expression. The 12 xenografts evaluated in the 
preclinical trial are identified, and clustered relative to 167 patient PDAC transcriptomes 
from the COMPASS trial (n = 164) and non-COMPASS patients (n = 3). The 21 HRD 
PDAC patients are indicated in black boxes. (b) Stepwise multivariable linear regression 
model of predictors of cisplatin response. (c) Stepwise multivariable linear regression 
model of predictors of talazoparib response


























Figure 6. 21 Clinical outcomes of 21 HRD PDAC patients with whole genome and 
whole transcriptomic sequencing. Kaplan-Meier survival curves are shown, stratified 
by tumour ploidy (a) and transcriptomic subtype (b). P-values represent log-rank 
comparisons. (c) Multivariable Cox regression analysis with forward stepwise selection, 
including age, sex, stage at diagnosis, tumour ploidy and Moffitt transcriptomic subtype. 
Tumour ploidy and Moffitt subtype were retained in the model and independently 






























Figure 7. Immunohistochemical biomarkers of 
Moffitt transcriptomic subtype in HRD PDAC. 
(a) TMM-normalized log2(CPM) gene expression 
values for GATA6, KRT17 and KRT81 between 
classical and basal-like subtypes in the cohort 
described in Fig. 7. GATA6 and KRT17 were the 
most significantly correlated with transcriptomic 
subtype, and were further evaluated with IHC. (b) 
Classical HRD PDAC was associated with 
significantly higher GATA6 positivity. GATA6 
immunostaining was quantified by digital image 
analysis using a tumor classifier and a nuclear 
scoring algorithm. (c) Basal-like HRD PDAC was 
associated with significantly higher KRT17 positivity, as assessed using a cytoplasmic scoring 
algorithm. (d) Combining both GATA6 and KRT17 as a GATA6:KRT17 ratio has higher 
predictive value than either marker alone. (e) Representative multiplex IHC stains showing 
GATA6 (brown) and KRT17 (teal). (Top row) Classical xenograft (O28) with predominantly 
GATA6+/KRT17- cells. (Middle row) Basal-like xenograft (S145) with predominantly GATA6-
/KRT17+ cells. (Bottom row) Basal-like xenograft (Q70P) with a mutually exclusive mixture of 





















Figure 8. Proposed schematic of predictors of chemosensitivity and prognosis in 




Figure Legends 730 
 731 
Figure 1. Genomic characteristics of patient-derived xenografts and preclinical 732 
trial outcomes. (a) Genomic characteristics of the 7 gBRCA-mutated PDAC cases 733 
evaluated in the preclinical trial. The first 6 cases have biallelic inactivation of BRCA1 or 734 
BRCA2. They exhibit mutational patterns that are characteristic of homologous repair 735 
deficiency, and have an elevated HRDetect score. In contrast, the Q437 case with 736 
monoallelic BRCA2 inactivation lacks these genomic HRD hallmarks and has a low 737 
HRDetect score. (b-c) 7-arm preclinical trial to evaluate response of PDAC xenografts to 738 
cisplatin, talazoparib and gemcitabine mono- and combination therapies. (b) HR-739 
deficient (6 unique cases, 228 mice) and (c) HR-proficient (B, 4 unique cases, 159 mice) 740 
PDAC xenografts were treated for 28 days. For each treatment arm, the relative tumour 741 
growth (at Day 28) of HR-deficient vs. HR-proficient xenografts was compared using 742 
multiple linear regression models. Tal, talazoparib; ** p < 0.01; *** p < 0.001. (d-e) 743 
Kaplan-Meier survival curves of xenografts treated with gemcitabine mono- and 744 
combination therapies. In HR-deficient xenografts, gemcitabine-cisplatin was associated 745 
with longer survival than gemcitabine alone and gemcitabine-talazoparib. There was no 746 
survival difference in HR-proficient xenografts. P-values represent log-rank comparisons 747 
of Kaplan-Meier survival curves. * p < 0.05, ** p < 0.01, ** p < 0.001. Cis, cisplatin; Tal, 748 
talazoparib. 749 
 750 
Figure 2. Histopathological and immunohistochemical analyses of proliferative 751 
activity in xenografts treated with gemcitabine mono- and combination therapies. 752 
(a) Comparison of relative Ki67 positivity of HR-deficient vs. HR-proficient xenografts for 753 
each treatment arm. * p < 0.05, *** p < 0.001. (b) Representative Ki67 immunostaining 754 
of Q392 (HR-deficient) vs. Q133 (HR-proficient) xenografts. GC, gemcitabine-cisplatin; 755 
GT, gemcitabine-talazoparib. (c) Pearson’s correlation between absolute Ki67 positivity 756 
and mitotic activity (# mitoses/10hpf) across all xenografts. 757 
 758 
Figure 3. Longitudinally derived xenografts from a patient with HRD PDAC (Q70) 759 
recapitulate the emergence of clinical chemoresistance. (a) Timeline showing the 760 
evolution of serum Ca19-9 in relation to chemotherapy. Arrows indicate when the 761 
individual xenografts (Q70P, Q70LM, Q70AM) were derived. Numbers correspond to 762 
cross-sectional imaging detailed in (B). (b) Representative computed tomography scans 763 
showing chemotherapy response at various time points. (1-2) Partial response of the 764 
pancreatic tail primary (Q70P) to FOLFIRINOX. (3-4) Partial response of the liver 765 
metastases (Q70LM) to FOLFIRINOX. (5-6) Worsening of peritoneal carcinomatosis 766 
(Q70AM) on gemcitabine-cisplatin. (c) Multi-arm preclinical trial results for the Q70P, 767 
Q70LM and Q70AM xenografts (n = 117 mice). For a given xenograft, day 29 tumour 768 
ratios were compared between each treatment arm (cisplatin, talazoparib, cisplatin-769 
talazoparib) and vehicle. The Q70AM xenograft showed resistance to cisplatin and 770 
talazoparib alone, but remained sensitivity to cisplatin-talazoparib combination. *** p < 771 
0.001; ns, not significant. Tal, talazoparib. 772 
 773 
Figure 4. Whole genome sequencing (WGS) of 4 matched HRD PDAC trios to 774 




patient primary, (2) untreated parent PDX (Pre), and (3) PDX treated with gemcitabine-776 
cisplatin and collected at trial endpoint (Post) are shown. Germline and somatic BRCA2 777 
mutations were conserved in all cases. The proportion of SBS3 remained stable in the 778 
gemcitabine-cisplatin-treated xenografts. (b) Evolution of neoantigen load between the 779 
patient, untreated parent PDX and PDX treated with gemcitabine-cisplatin. (c) Multiplex 780 
IHC stains showing spatial distribution of CD8+ (brown) cytotoxic T cells and pan-781 
cytokeratin+ (teal) PDAC cells. Consistent with the increase in in silico-predicted 782 
neoantigens, there is an increase in CD8+ infiltration in the Q70AM tumour compared to 783 
the Q70P. However, the CD8+ infiltration remained less extensive compared to an 784 
MMR-deficient PDAC (MMRd). 785 
 786 
Figure 5. Predictive biomarkers identified based on preclinical trial treatment responses. 787 
(a) Consensus clustered heatmap of PDAC transcriptomes split by Moffitt classical and 788 
basal-like factor gene expression. The 12 xenografts evaluated in the preclinical trial are 789 
identified, and clustered relative to 167 patient PDAC transcriptomes from the 790 
COMPASS trial (n = 164) and non-COMPASS patients (n = 3). The 21 HRD PDAC 791 
patients are indicated in black boxes. (b) Stepwise multivariable linear regression model 792 
of predictors of cisplatin response. (c) Stepwise multivariable linear regression model of 793 
predictors of talazoparib response. 794 
 795 
Figure 6. 21 Clinical outcomes of 21 HRD PDAC patients with whole genome and 796 
whole transcriptomic sequencing. Kaplan-Meier survival curves are shown, stratified 797 
by tumour ploidy (a) and transcriptomic subtype (b). P-values represent log-rank 798 
comparisons. (c) Multivariable Cox regression analysis with forward stepwise selection, 799 
including age, sex, stage at diagnosis, tumour ploidy and Moffitt transcriptomic subtype. 800 
Tumour ploidy and Moffitt subtype were retained in the model and independently 801 
associated with survival. Hazard ratios and 95% confidence intervals are shown. 802 
 803 
Figure 7. Immunohistochemical biomarkers of Moffitt transcriptomic subtype in 804 
HRD PDAC. (a) TMM-normalized log2(CPM) gene expression values for GATA6, 805 
KRT17 and KRT81 between classical and basal-like subtypes in the cohort described in 806 
Fig. 7. GATA6 and KRT17 were the most significantly correlated with transcriptomic 807 
subtype, and were further evaluated with IHC. (b) Classical HRD PDAC was associated 808 
with significantly higher GATA6 positivity. GATA6 immunostaining was quantified by 809 
digital image analysis using a tumor classifier and a nuclear scoring algorithm. (c) 810 
Basal-like HRD PDAC was associated with significantly higher KRT17 positivity, as 811 
assessed using a cytoplasmic scoring algorithm. (d) Combining both GATA6 and 812 
KRT17 as a GATA6:KRT17 ratio has higher predictive value than either marker alone. 813 
(e) Representative multiplex IHC stains showing GATA6 (brown) and KRT17 (teal). 814 
(Top row) Classical xenograft (O28) with predominantly GATA6+/KRT17- cells. (Middle 815 
row) Basal-like xenograft (S145) with predominantly GATA6-/KRT17+ cells. (Bottom 816 
row) Basal-like xenograft (Q70P) with a mutually exclusive mixture of GATA6-/KRT17+ 817 
cells and GATA6+/KRT17- cells, suggesting intratumoral heterogeneity. 818 
 819 
Figure 8. Proposed schematic of predictors of chemosensitivity and prognosis in 820 
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